Australia's Memphasys jumps on European regulatory approval for product

Memphasys

28/12/2025 23:59

** Shares of Memphasys MEM.AX rise as much as 60% to A$0.008, their highest level since April 3

** Stock set for strongest trading session since September 8, if current trends hold

** Biotech co granted Conformité Européenne (CE) mark approval for its Felix automated sperm selection system

**  CE Mark confirms that Felix complies with the European Union Medical Device Regulation - co

** Around 43.4 mln shares change hands, 7.5x the 30-day avg volume

** YTD, stock up 5%, including the day's moves

 (Reporting by Shivangi Lahiri in Bengaluru)

 ((shivangi.lahiri@thomsonreuters.com))